PREVENTION OF OVARIAN CANCER BY ADMINISTRATION OF AGENTS THAT INDUCE BIOLOGIC RESPONSES
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to compositions and methods for preventing the development of epithelial ovarian cancer by administering compounds in an amount capable of regulating TGF-β expression in the ovarian epithelium and/or capable of optimally altering expression of other surrogate biomarkers identified by microarray technology. HRT and OCP regimens comprising such compositions and methods are disclosed.
-
Citations
108 Claims
-
1-33. -33. (canceled)
- 34. A composition comprising genistein and a Vitamin D compound wherein the daily dosage of said Vitamin D compound is greater than 400 IU.
- 46. A composition comprising a Vitamin D compound and an isoflavone compound selected from the group consisting of genistein, forms of genistin, and combinations thereof, wherein the daily dosage of said Vitamin D compound is greater than 400 IU.
- 59. A composition comprising daidzein and a Vitamin D compound wherein the daily dosage of said Vitamin D compound is greater than 400 IU.
- 71. A composition comprising a Vitamin D compound and an isoflavone compound selected from the group consisting of daidzein, forms of daidzin, and combinations thereof, wherein the daily dosage of said Vitamin D compound is greater than 400 IU.
- 85. A composition comprising a glycitein and a Vitamin D compound wherein the daily dosage of said Vitamin D compound is greater than 400 IU.
- 97. A composition comprising a Vitamin D compound and an isoflavone compound selected from the group consisting of glycitein, forms of glycitin, and combinations thereof, wherein the daily dosage of said Vitamin D compound is greater than 400 IU.
Specification